Article
Oncology
Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, James R. Kiefer, Melissa M. Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Sivan Cohen, Srividya Myneni, Luna Liu, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida Nagata, Shelly Zhong, Steven R. Leong, Ji Li, Rin Nakamura, Teiko Sumiyoshi, Jinze Li, Ayse Meric Ovacik, Bing Zheng, Mike Dillon, Christoph Spiess, Susanne Wingert, Erich Rajkovic, Kristina Ellwanger, Uwe Reusch, Andrew G. Polson
Summary: Despite the current incurability of multiple myeloma (MM), the novel treatment, RO7297089, shows potential as an effective and well-tolerated therapy. By targeting BCMA and CD16A, RO7297089 induces lysis of MM cells and has a favorable safety profile, as evidenced by in vitro cytokine release and animal studies.
Article
Immunology
Xinghui Xiao, Ying Cheng, Xiaodong Zheng, Yuhang Fang, Yu Zhang, Rui Sun, Zhigang Tian, Haoyu Sun
Summary: Bispecific antibodies that target CD3 have been widely used in tumor treatment, but may cause severe side effects. Our study developed two IgG-like bispecific antibodies, BK1 and BT1, which targeted NK cells and T cells, respectively. It was found that BK1 had a stronger antitumor effect and induced fewer proinflammatory cytokines compared to BT1. Combining BK1 with BT1 further reduced cytokine secretion by T cells, suggesting a promising future for NK-cell engagers in clinical settings.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Ulrike Protzer
Summary: Despite the availability of a prophylactic vaccine, many people still die from hepatitis B virus (HBV)-related liver disease. Current antiviral therapies are not curative, so new strategies are urgently needed. This study explores the use of bi- and trispecific T-cell engager antibodies as an alternative treatment for HBV.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Bailis, Matthias Friedrich
Summary: AMG 596 is a potential drug for GBM treatment with highly specific and potent T-cell activation capabilities, increasing survival rate in mice and showing promising preclinical efficacy.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Jinrong Yang, Weilin Zhou, Dan Li, Ting Niu, Wei Wang
Summary: This article summarizes the application and research progress of BCMA-targeting CAR T cell therapy in the treatment of multiple myeloma, as well as measures to improve efficacy and safety.
Article
Biochemistry & Molecular Biology
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Sandra Schnakenberg, Deepu Madduri, Somali Gavane, Julie Teruya-Feldstein, John F. Crary, Mary E. Fowkes, Charles B. Stacy, Seunghee Kim-Schulze, Adeeb Rahman, Alessandro Lagana, Joshua D. Brody, Miriam Merad, Sundar Jagannath, Samir Parekh
Summary: The study presents a case of a multiple myeloma patient who developed parkinsonism symptoms after receiving BCMA-targeted CAR-T cell therapy, highlighting the importance of close neurological monitoring for patients on such therapies.
Article
Engineering, Biomedical
Seil Jang, Jaeho Song, NaYoung Kim, Jeonghyeon Bak, Keehoon Jung, Young Woo Park, Bum-Chan Park, Ho Min Kim
Summary: The development of bispecific antibodies, such as ACE-05, using the ALiCE platform shows promising potential for anti-cancer immunotherapy. These antibodies have dual roles in immune checkpoint inhibition and T-cell redirection while reducing off-target toxicity. In preclinical studies, ACE-05 demonstrated marked antitumor efficacy and complete tumor regression in humanized mouse models, suggesting its potential as a therapeutic agent for cancer treatment.
Article
Medicine, Research & Experimental
Liping Zhong, Wei Shi, Lu Gan, Xiuli Liu, Yu Huo, Pan Wu, Zhikun Zhang, Tao Wu, Hongmei Peng, Yong Huang, Yongxiang Zhao, Yulin Yuan, Zhiming Deng, Hongliang Tang
Summary: A bispecific T-cell engager antibody targeting human endoglin and CD3 was constructed in this study, showing therapeutic potential in cancer treatment. In vivo experiments demonstrated that the antibody significantly reduced tumor growth and neoangiogenesis, leading to improved mouse survival.
Article
Oncology
Liang Lin, Shih-Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li, Tengteng Yu, Phillip A. Hsieh, Hailin Chen, Metin Kurtoglu, Yi Zhang, C. Andrew Stewart, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Summary: The study introduces a novel CD8+ CAR T-cell product, Descartes-08, for the treatment of multiple myeloma, with predictable pharmacokinetics and limited risks of uncontrolled proliferation and drug resistance. Preclinical data and ongoing clinical trials have demonstrated the effectiveness and safety of Descartes-08 in inhibiting myeloma growth and providing durable responses in patients.
Article
Oncology
Upasana Sunil Arvindam, Paulien M. M. van Hauten, Dawn Schirm, Nicolaas Schaap, Willemijn Hobo, Bruce R. Blazar, Daniel A. Vallera, Harry Dolstra, Martin Felices, Jeffrey S. Miller
Summary: The development of a CLEC12A TriKE molecule targeting AML blasts and LSCs, which activates NK cells and drives NK cell priming while sparing healthy cells, highlights the potential clinical efficacy for the treatment of AML.
Article
Chemistry, Multidisciplinary
Dingkang Liu, Lichen Bao, Haichao Zhu, Yali Yue, Jing Tian, Xiangdong Gao, Jun Yin
Summary: This study developed a Protease-Activated PSTAGylated BiTE called PAPB, which showed long-acting and highly effective anti-tumor activity in solid tumors. PAPB could release BiTE core to exert its therapeutic effect, and significantly increase T lymphocyte infiltration in tumor tissue. This engineered protein has potential as a promising drug candidate for solid tumor immunotherapy.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Immunology
Ruiting Guo, Wenyi Lu, Yi Zhang, Xinping Cao, Xin Jin, Mingfeng Zhao
Summary: BCMA plays a significant role in the treatment of multiple myeloma, and various BCMA-targeted immunotherapies have made significant progress.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lisa A. King, Elisa C. Toffoli, Myrthe Veth, Victoria Iglesias-Guimarais, Manon C. Slot, Derk Amsen, Rieneke van de Ven, Sarah Derks, Marieke F. Fransen, Jurriaan B. Tuynman, Thilo Riedl, Rob C. Roovers, Anton E. P. Adang, Jurjen M. Ruben, Paul W. H. I. Parren, Tanja D. de Gruijl, Hans J. van der Vliet
Summary: This study assessed the antitumor activity and safety of a bispecific antibody that activates Vy9V82 T cells. In vitro, in vivo, and ex vivo experiments were conducted, and safety was evaluated in nonhuman primates. The findings demonstrated the potential of the antibody to activate Vy9V82 T cells for antitumor activity and its acceptable safety profile, providing a solid basis for further testing in patients with EGFR-positive malignancies.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Oncology
Liora Schultz, Kara Lynn Davis, Ann Walkush, Christina Baggott, Courtney Erickson, Sneha Ramakrishna, Catherine Aftandilian, Norman Lacayo, Helen Ruth Nadel, Jean Oak, Crystal L. Mackall
Summary: Chimeric antigen receptor (CAR) T cell therapy is effective for pediatric relapsed B-cell acute lymphoblastic leukemia (B-ALL), but high rates of post-CAR relapse are a challenge. This study highlights the importance of integrating peripheral blood minimal residual disease (MRD) testing and radiologic imaging into surveillance strategies to effectively detect post-CAR relapse.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Abhinava K. Mishra, Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty, Shabirul Haque, Chandra Prakash Prasad, Archana Singh, Ajaz A. Bhat, Muzafar A. Macha, Moez Benali, Kamal S. Saini, Rebecca Ann Previs, Deepak Saini, Dwaipayan Saha, Preyangsee Dutta, Aseem Rai Bhatnagar, Mrinalini Darswal, Abhishek Shankar, Mayank Singh
Summary: Significant progress has been made in the treatment of multiple myeloma, with CAR-T cell therapy showing promise as a cellular treatment option, particularly with BCMA as the target antigen. However, there are challenges such as antigenic escape and potential adverse reactions associated with CAR-T cell therapy.